#United States #Carlsbad #Tyra Biosciences #FGFR3 #Dabogratinib

Tyra Biosciences Highlights Progress in Q3 2026

Tyra Biosciences, Inc. (Nasdaq: TYRA), a pioneering biotechnology firm focused on creating advanced precision medicines, reported notable financial outcomes and advancements in clinical developments for the third quarter of 2026, recently culminating on September 30. With an emphasis on the company's flagship product, dabogratinib, Tyra is setting new benchmarks in the treatment of cancer, particularly targeting non-muscle invasive bladder cancer (NMIBC).

Financial Milestones and Key Developments

In a significant move, Tyra raised $400 million through a public stock offering, bolstering its resources to pursue its innovative dabogratinib strategy. With $700.5 million in cash and marketable securities as of the quarter’s end, the company has ensured a robust cash runway extending through 2030. This financial foundation positions Tyra favorably for ongoing research and development initiatives while enhancing its operational capabilities.

Todd Harris, PhD, the President and CEO of Tyra, expressed optimism regarding dabogratinib’s potential: “2026 has been a defining year for TYRA. The initial data from our SURF302 study reveals that dabogratinib may become the first oral FGFR3-selective inhibitor for IR NMIBC patients, paving the way for transformative changes in cancer treatment.” Harris emphasized the necessity of addressing the chronic cycles of procedures faced by cancer patients, indicating that Tyra’s advancements offer hope for a more sustainable therapeutic option.

Clinical Developments: Dabogratinib Shows Promise

Tyra's Phase 2 SURF302 trial has provided promising insights with oral dabogratinib showing:
Overall Response Rate (ORR): 79%
Best Overall Response Rate (BOR): 64% CR
* In a more focused analysis of participants with a singular marker, 100% ORR and 75% BOR CR were documented. This data reaffirms the drug's potential efficacy and its possible role in changing treatment protocols for patients dealing with these challenging cancer types.

Initial safety results have also been favorable, with no significant adverse events reported, marking a promising pathway towards Phase 3 study initiation expected in 2027. The successful completion of enrollment in the 60 mg cohort and ongoing enrollment in higher dose cohorts further underscores the company’s commitment to advancing clinical understanding of dabogratinib’s effectiveness.

Looking Ahead: Future Studies and Expanding Horizons

Tyra is not stopping with bladder cancer; it is also advancing the dabogratinib 3x3 strategy which encompasses pivotal research into low-grade upper tract urothelial carcinoma (LG-UTUC) and skeletal dysplasias. With the initial patient in the SURF303 study achieving complete response, Tyra aims to deliver additional findings in 2027, shining a light on the broader applicability of this treatment paradigm.

Moreover, the BEACH301 trial involving pediatric patients with achondroplasia is making strides, with favorable conditions allowing the exploration of multiple dosing levels for safety assessments. This comprehensive approach illustrates Tyra's commitment to targeting conditions often overlooked or inadequately addressed in the pharmaceutical landscape.

Conclusion

As Tyra Biosciences progresses through 2026, the implications of its clinical trials and strong financial backing signify an era of potential reform in cancer therapeutics. The advancement of dabogratinib represents more than a single drug; it embodies a commitment to patient-centric innovation in biotechnology. With its strong pipeline and strategic financing, Tyra stands poised to make a lasting impact on treatment methodologies, pushing the boundaries of what is possible in targeted medicine.